Literature DB >> 18178205

The natural history of aberrant crypt foci.

Robert E Schoen1, Matthew Mutch, Christopher Rall, Sarah M Dry, David Seligson, Asad Umar, Paul Pinsky.   

Abstract

BACKGROUND: Aberrant crypt foci (ACF) are the putative precursors to colorectal adenomas and may be useful as biomarkers. Knowledge of their natural history is essential to understanding their potential utility.
OBJECTIVE: Our purpose was to examine ACF detection 1 year after initial observation.
DESIGN: We conducted a multicenter study of ACF by using a standardized protocol. ACF in the rectum were assessed and subjects returned 1 year later to evaluate the natural history of the lesions.
SETTING: Ancillary study to the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
RESULTS: Of 78 subjects enrolled, 64 (82%) returned for a repeat examination 1 year later. The mean age was 71 years, 70% were male, and 54% had a history of adenomatous polyps. At the initial examination, 66% of subjects had at least 1 ACF detected in the rectum, with a mean of 2.1 +/- 2.3 per person. One year later, 60% of these subjects had at least 1 of the original ACF reidentified, but only 43% of all ACF were reidentified. A total of 56% of subjects had new ACF identified. LIMITATIONS: These results are generated from the pilot phase. Improvements or change in technique over time could have influenced the results.
CONCLUSIONS: A total of 60% of subjects who had ACF continued to have at least one ACF 1 year later, but less than half the specific ACF could be reidentified, and more than 50% of subjects had new ACF. These results imply a considerable dynamic to ACF detection over a 1-year period of observation.

Entities:  

Mesh:

Year:  2008        PMID: 18178205     DOI: 10.1016/j.gie.2007.08.048

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  7 in total

1.  Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.

Authors:  Paul J Limburg; Michelle R Mahoney; Katie L Allen Ziegler; Stephen J Sontag; Robert E Schoen; Richard Benya; Michael J Lawson; David S Weinberg; Elena Stoffel; Michael Chiorean; Russell Heigh; Joel Levine; Gary Della'Zanna; Luz Rodriguez; Ellen Richmond; Christopher Gostout; Sumithra J Mandrekar; Thomas C Smyrk
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-05

2.  One year recurrence of aberrant crypt foci.

Authors:  Paul F Pinsky; James Fleshman; Matt Mutch; Christopher Rall; Aline Charabaty; David Seligson; Sarah Dry; Asad Umar; Robert E Schoen
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-22

3.  Relationship of human rectal aberrant crypt foci and formation of colorectal polyp: One-year following up after polypectomy.

Authors:  Hirokazu Takahashi; Eiji Yamada; Hidenori Ohkubo; Eiji Sakai; Takuma Higurashi; Takashi Uchiyama; Kunihiro Hosono; Hiroki Endo; Atsushi Nakajima
Journal:  World J Gastrointest Endosc       Date:  2012-12-16

4.  Reliability and accuracy of the endoscopic appearance in the identification of aberrant crypt foci.

Authors:  Akshay K Gupta; Paul Pinsky; Christopher Rall; Matthew Mutch; Sarah Dry; David Seligson; Robert E Schoen
Journal:  Gastrointest Endosc       Date:  2009-06-21       Impact factor: 9.427

5.  Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

Authors:  Helen Swede; Thomas E Rohan; Herbert Yu; Joseph C Anderson; Richard G Stevens; Jane Brokaw; Joel Levine; Bruce M Brenner; Carl D Malchoff; Valerie B Duffy; Devon C Pleau; Daniel W Rosenberg
Journal:  Cancer Causes Control       Date:  2008-12-09       Impact factor: 2.506

Review 6.  The natural history of colorectal adenomas and early cancer.

Authors:  M Risio
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

7.  Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk.

Authors:  Isabel Quintanilla; María López-Cerón; Mireya Jimeno; Miriam Cuatrecasas; Michel Zabalza; Leticia Moreira; Virginia Alonso; Cristina Rodríguez de Miguel; Jennifer Muñoz; Sergi Castellvi-Bel; Josep Llach; Antoni Castells; Francesc Balaguer; Jordi Camps; Maria Pellisé
Journal:  Clin Transl Gastroenterol       Date:  2019-06       Impact factor: 4.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.